Prudential Financial
SABS icon

Prudential Financial’s SAB Biotherapeutics SABS Stock Holding History

Prudential Financial’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-3,620
Closed -$30K – 2687
2023
Q2 		$30K Buy
+3,620
New +$29.7K ﹤0.01% 2584

Other funds holding SABS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FPB
First PREMIER Bank Sioux Falls, South Dakota $619M AUM 20.21% 1-Year Est. Return
PFO
Pathstone Family Office Englewood, New Jersey $13.1B AUM 21.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
IFAM
Institutional & Family Asset Management Fort Collins, Colorado $654M AUM 12.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
Mariner
Mariner Overland Park, Kansas $85.7B AUM 24.21% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Prudential Financial's SABS Position: Q3 2023 in Review

Prudential Financial sold out of SAB Biotherapeutics (SABS) in Q3 2023, closing a stake of 3,620 shares — an estimated $30K sold.

Prudential Financial first reported a position in SABS in Q2 2023 and held it in 1 quarter. The position peaked at $30K in Q2 2023. 34 funds tracked by Wall St. Rank hold SABS as of Q3 2023.

  • Prudential Financial reported no remaining SAB Biotherapeutics position as of Q3 2023 after selling out during the quarter.
  • Prudential Financial sold 3,620 SAB Biotherapeutics shares in Q3 2023, an estimated $30K.
  • Prudential Financial first reported a position in SAB Biotherapeutics in Q2 2023 and held it in 1 quarter.
  • Prudential Financial's SAB Biotherapeutics position peaked at $30K in Q2 2023.
  • 34 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q3 2023.

Based on Prudential Financial's 13F filing for Q3 2023, filed 13 Nov 2023.